Key result
The POLARx cryoballoon system demonstrated similar acute procedural efficacy and safety compared to the Arctic Front Advance Pro system, but had a significantly higher likelihood of time-to-isolation recording in the inferior pulmonary veins.
Why the study?
Initial experience suggested similar efficacy and safety between POLARx and Arctic Front Advance Pro, prompting an updated systematic review and meta-analysis comparing the two cryoballoon systems.
Does the POLARx cryoballoon system have similar acute procedural efficacy and safety compared to the AFA-Pro system in patients undergoing pulmonary vein isolation for atrial fibrillation?
Meta-Analysis (n=1,146)
Yes
Does the POLARx cryoballoon system have similar acute procedural efficacy and safety compared to the AFA-Pro system in patients undergoing pulmonary vein isolation for atrial fibrillation?
The novel POLARx cryoballoon system demonstrates similar acute procedural efficacy and safety compared to the established AFA-Pro system for pulmonary vein isolation in atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports POLARx as an alternative to AFA-Pro for acute PVI; extends comparative cryoballoon evidence on inferior vein TTI recording.
Initial experience suggests that the POLARx cryoballoon system (Boston Scientific) has a similar procedural efficacy and safety as Arctic Front Advance Pro (AFA-Pro, Medtronic). We performed an updated systematic review and meta-analysis comparing POLARx and AFA-Pro. Embase, MEDLINE, Web of Science, Cochrane, and Google Scholar databases were searched until 12/01/2022 for studies comparing POLARx versus AFA-Pro in patients undergoing pulmonary vein (PV) isolation for AF. A total of 8 studies, involving 1146 patients from 11 European centers were included (POLARx n = 317; AFA-Pro n = 819). There were no differences in acute PV isolation, procedure time, fluoroscopy time, ablation time, minimal esophageal temperature, and risk of phrenic nerve palsy or thromboembolic events. Balloon nadir temperatures were lower for POLARx in all PVs. Compared with AFA-Pro, POLARx had a higher rate of first freeze isolation in the left inferior PV (LIPV) (odds ratio [OR]: 2.60; 95 % confidence interval [CI]: 1.06 to 6.43; P = 0.04), higher likelihood of time-to-isolation (TTI) recording in LIPV (OR: 2.91; 95 % CI: 1.54 to 5.49; P = 0.001) and right inferior PV (OR: 3.23; 95 % CI: 1.35 to 7.74; P = 0.008). In contrast, the TTI in LIPV was longer with POLARx in comparison to AFA-Pro (mean difference: 7.61 sec; 95 % CI 2.43 to 12.8 sec; P = 0.004). In conclusion, POLARx and AFA-Pro have a similar acute outcome. Interestingly, there was a higher rate of TTI recording in the inferior PVs with POLARx. This updated meta-analysis provides new safety data on esophageal temperature and thromboembolic events.
No takes yet. Share an insight, caveat, or question.
Assaf et al. (2022) conducted a meta-analysis in Atrial fibrillation (n=1,146). POLARx cryoballoon vs. Arctic Front Advance Pro (AFA-Pro) cryoballoon was evaluated on Time-to-isolation (TTI) recording in the left inferior pulmonary vein (LIPV) (OR 2.91, 95% CI 1.54 to 5.49, p=0.001). The POLARx cryoballoon system demonstrated similar acute procedural efficacy and safety compared to the Arctic Front Advance Pro system, but had a significantly higher likelihood of time-to-isolation recording in the inferior pulmonary veins.
Synapse has enriched 10 related papers. Consider them for comparative context: